PRPO (Precipio) 5-Year Yield-on-Cost %: 0.00 (As of Aug. 11, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PRPO Precipio Inc PRPO
53 GF Score
Price $22.09
GF Value $10.74
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Precipio 5-Year Yield-on-Cost %?

Precipio PRPO -1.11% 53 5-Year Yield-on-Cost % is 0.00 as of Aug. 11, 2026. GuruFocus rates PRPO with a GF Score™ of 53/100 and a GF Value™ of $10.74 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 63 Medical Diagnostics & Research companies, Precipio ranks worse than 1587300% on this metric.

Precipio's yield on cost for the quarter that ended in Mar. 2026 was 0.00.


The historical rank and industry rank for Precipio's 5-Year Yield-on-Cost % or its related term are showing as below:



PRPO's 5-Year Yield-on-Cost % is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 2.42
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Precipio  (NAS:PRPO) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Precipio 5-Year Yield-on-Cost % Related Terms


PRPO vs IDXG, ADVB, BIOQ: 5-Year Yield-on-Cost % Comparison

For the Diagnostics & Research subindustry, Precipio's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Precipio 5-Year Yield-on-Cost % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Precipio's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Precipio's 5-Year Yield-on-Cost % falls into.


PRPO
53GF Score
Precipio Inc PRPO
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Precipio 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Precipio is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
Precipio (PRPO) has a 5-Year Yield-on-Cost % of 0.00 as of Aug. 11, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Precipio and its competitors. According to the industry distribution chart, Precipio ranks #999999 out of 63 companies in the Medical Diagnostics & Research industry.
Is Precipio's 5-Year Yield-on-Cost % too high?
Precipio's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Precipio ranks #999999 out of 63 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Precipio has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Precipio's 5-Year Yield-on-Cost % compare to IDXG and ADVB?
According to the Medical Diagnostics & Research industry distribution chart, Precipio ranks #999999 out of 63 companies for 5-Year Yield-on-Cost %. This places Precipio in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.42. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Diagnostics & Research company?
The median 5-Year Yield-on-Cost % among Medical Diagnostics & Research companies is 2.42, based on 63 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Precipio and its competitors. For the Medical Diagnostics & Research industry, the median 5-Year Yield-on-Cost % is 2.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Precipio's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Precipio stock overvalued right now?
Based on GuruFocus' analysis, Precipio (PRPO) is currently considered Significantly Overvalued. The stock's GF Value™ is $10.74, compared to a current price of $22.09 — trading 105.7% above its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Precipio's overall GF Score™ is 53/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Precipio (PRPO), the current 5-Year Yield-on-Cost % is 0.00 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Precipio (PRPO) Overvalued in 2026?

Based on GuruFocus' analysis, Precipio stock appears to be overvalued. The current stock price of $22.09 is trading 105.7% above its estimated GF Value™ of $10.74. GuruFocus considers Precipio to be Significantly Overvalued.

Key valuation signals for PRPO:

  • 5-Year Yield-on-Cost %: 0.00
  • GF Value™: $10.74 vs. price of $22.09 (105.7% above fair value)
  • GF Score™: 53/100 with 2 warning signs

No single metric tells the full story. See the PRPO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Precipio Business Description

Address 4 Science Park, 3rd Floor, New Haven, CT, USA, 06511
Precipio Inc is a healthcare biotechnology company focused on cancer diagnostics. Its objective is to enhance diagnostic accuracy & accessibility while building a sustainable business model that supports ongoing innovation. The company operates Clinical Laboratory Improvement Amendments laboratories in both New Haven, Connecticut, & Omaha, Nebraska, providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. The company operates in a single segment, which includes two divisions: the Pathology Services Division & the Products Division. The Pathology Services provides specialized cancer diagnostic testing services. The pathology services division specializes in diagnostic testing focused mainly on hematologic cancers.
53GF Score

Get the complete analysis for PRPO

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$22.09
Price
$10.74
GF Value